A 35-year-old woman with biopsy-proven SLE (4 years' duration) on hydroxychloroquine and prednisolone 10 mg daily presents with a 3-month history of progressive dyspnea, pleuritic chest pain, and a new pleural effusion on chest X-ray. Pleural fluid analysis shows LE cells present, ANA positive, and low complement. She is afebrile; blood cultures are negative. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has SLE with **lupus pleuritis** (serositis), evidenced by pleural effusion with LE cells, ANA positivity, and low complement in pleural fluid. She is afebrile with negative blood cultures, making infection unlikely. ## Diagnosis of Lupus Pleuritis **Key Point:** Serositis (pleuritis, pericarditis, peritonitis) is a common SLE manifestation. Diagnosis is supported by: - Clinical features (pleuritic pain, dyspnea) - Pleural fluid with LE cells or ANA positivity - Low complement in fluid - Exclusion of infection **High-Yield:** LE cells in pleural fluid are highly specific for lupus serositis and essentially confirm the diagnosis when combined with clinical context. ## Management of Lupus Pleuritis ### Rationale for Correct Answer 1. **Increase corticosteroids** to 0.5–1 mg/kg/day (typically 40–60 mg prednisolone) is the standard first-line therapy for active serositis 2. **Add azathioprine** (1–2 mg/kg/day) as a steroid-sparing agent to allow gradual prednisolone taper and reduce relapse risk 3. **Close monitoring** with repeat imaging at 4 weeks assesses response 4. **No need for urgent intervention** — serositis is not immediately life-threatening and responds well to immunosuppression ### Why Thoracentesis Is Not Urgent Here **Clinical Pearl:** Thoracentesis was already performed (pleural fluid analysis provided). Repeat thoracentesis is not indicated unless: - Diagnosis remains uncertain - Infection is suspected (fever, positive cultures, clinical deterioration) - Fluid is loculated and causing respiratory compromise This patient is afebrile with negative cultures — infection is ruled out. ## Serositis Management Algorithm ```mermaid flowchart TD A[SLE with pleuritis/serositis]:::outcome --> B{Infection excluded?}:::decision B -->|No fever, negative cultures| C[Lupus serositis confirmed]:::outcome B -->|Fever or positive culture| D[Treat infection first]:::action C --> E[Increase prednisolone 0.5-1 mg/kg/day]:::action E --> F[Add azathioprine or MMF]:::action F --> G[Repeat imaging in 4 weeks]:::decision G -->|Improved| H[Gradual steroid taper]:::action G -->|Persistent| I[Escalate to cyclophosphamide]:::urgent ``` **Key Point:** Serositis typically resolves within 2–4 weeks of corticosteroid escalation. Pleurodesis is reserved for recurrent, refractory effusions unresponsive to medical therapy. ## Steroid-Sparing Agents in SLE | Agent | Dose | Onset | Indication | |-------|------|-------|------------| | Azathioprine | 1–2 mg/kg/day | 6–8 weeks | Steroid-sparing, general SLE | | Mycophenolate | 1–3 g/day | 4–6 weeks | Nephritis, steroid-sparing | | Cyclophosphamide | 500–1000 mg/m² IV monthly | 2–4 weeks | Severe/refractory disease | **High-Yield:** Azathioprine is preferred here because serositis alone does not require the intensity of cyclophosphamide, and azathioprine has a good safety profile for long-term use.